慢性丙型肝炎患者血清和外泌体LncRNA HEIH水平及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2021.06.014

摘要/Abstract

摘要： 目的探讨慢性丙型肝炎(CHC)患者血清和外泌体肝细胞癌中高表达的中长链非编码RNA(long non-coding RNA HEIH,LncRNA-HEIH)水平变化及其临床意义。方法 2017年9月～2020年7月我院诊治的77例CHC患者和同期40例肝细胞癌(HCC)患者,采用定量RT-PCR法检测血清和外泌体LncRNA HEIH水平。CHC患者接受标准抗病毒治疗和肝活检。采用多元Logistic回归分析,应用ROC曲线分析血清和外泌体LncRNA HEIH水平预测肝组织病变的价值。结果 CHC患者血清和外泌体LncRNA HEIH水平分别为(2.3±0.2)和(3.6±0.6),均显著低于HCC患者【分别为(13.4±2.5)和(8.6±1.5),P<0.05】;53例肝组织炎症G0～G1患者血清和外泌体LncRNA HEIH水平分别为(2.5±0.3)和(3.9±0.6),显著高于24例肝组织炎症>G2者【分别为(1.9±0.4)和(2.9±0.5),P<0.05】,62例肝纤维化S0～S1患者血清和外泌体LncRNA HEIH水平分别为(2.6±0.4)和(4.1±0.7),均显著高于15例肝纤维化>S2者【分别为(1.6±0.4)和(2.5±0.5),P<0.05】;59例对抗病毒治疗应答组血清和外泌体LncRNA HEIH水平分别为(2.8±0.4)和(4.1±0.6),均显著高于18例不应答组【分别为(2.1±0.5)和(3.4±0.6),P<0.05】;CHC患者血清和外泌体LncRNA HEIH水平预测肝组织显著炎症或纤维化的AUC分别为0.764～0.778和0.723～0.736之间,具有一定的临床意义。结论 CHC患者血清和外泌体LncRNA HEIH水平异常,监测它们的变化可能对预测肝组织炎症分级和肝纤维化分期有帮助。

关键词: 慢性丙型肝炎, 外泌体, 肝细胞癌中高表达的中长链非编码RNA, 临床意义

Abstract: Objective The aim of this study was to explore the clinical implication of long non-coding RNA high expression in HCC (LncRNA-HEIH) in serum and exosomes in patients with chronic hepatitis C (CHC). Methods 77 patients with CHC and 40 CHC and 40 patients with hepatocellular carcinoma (HCC) were recruited in this study betweenSeptember 2017 and July 2020, and LncRNA HEIH in serum and exosomes were detected by RT-PCR. The patients received peg-interferon-α and ribavirin therapy for six months and liver biopsies. The multivariate Logistics regression analysis was done, and the prognostic value of LncRNA HEIH in serum and exosomes was analyzed by ROC curves. Results Serum and exosome LncRNA HEIH levels in patients with CHC were (2.3±0.2) and (3.6±0.6), both significantly lower than [(13.4±2.5) and (8.6±1.5), respectively, P<0.05] in patients with HCC; serum and exosome LncRNA HEIH levels in 53 patients with hepatic G0-G1 inflammatory activity were (2.5±0.3) and (3.9±0.6), significantly higher than [(1.9±0.4) and (2.9±0.5), respectively, P<0.05] in 24 patients with significant hepatic inflammatory activity (>G2), and serum and exosome LncRNA HEIH levels in 62 patients with S0-S1 hepatic fibrosis were (2.6±0.4) and (4.1±0.7), significantly higher than [(1.6±0.4) and (2.5±0.5), respectively, P<0.05] in 15 patients with significant hepatic fibrosis (>S2); serum and exosome LncRNA HEIH levels in 59 CHC patients responsive to antiviral therapy were (2.8±0.4) and (4.1±0.6), both significantly higher than [(2.1±0.5) and (3.4±0.6), respectively, P<0.05] in 18 patients nonresponsive to antiviral therapy; the AUC of serum and exosome LncRNA HEIH levels in predicting significant liver histologic activity index (HAI) or hepatic fibrosis were 0.764-0.778 or 0.723-0.736, suggesting some valuable in clinical practice. Conclusion Abnormal serum and exosome LncRNA HEIH levels exist in patients with CHC patients, and the surveillance of them might help predict the hepatic HAI and the response to antiviral therapy.

Key words: Hepatitis C, Exosome, Long non-coding RNA high expression in HCC, Clinical implication

贾坤, 苏建荣, 孙伟. 慢性丙型肝炎患者血清和外泌体LncRNA HEIH水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(6): 823-826.

Jia Kun, Su Jianrong, Sun Wei. Clinical implication of LncRNA HEIH in serum and exosomes in patients with chronic hepatitis C[J]. Journal of Practical Hepatology, 2021, 24(6): 823-826.

参考文献

[1] 卓丽, 许敏, 邓浩辉. 阿舒瑞韦联合达拉他韦治疗慢性丙型肝炎患者初步疗效及其病毒准种变化和耐药变异特征分析. 实用肝脏病杂志, 2020, 23(4):504-507.
[2] Cheng HR, Kao JH, Wu H, et al. Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. Hepatol Int, 2015, 9(1):35-42.
[3] Wang S, Chen Y, Xu X, et al. Prevalence of hepatitis B virus and hepatitis C virus infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Oncotarget, 2017, 60(8):102437-102445.
[4] 中华医学会肝病学分会和感染病学分会. 丙型肝炎防治指南(2015年更新版).实用肝脏病杂志, 2016, 19(4):ⅠⅩ-ⅩⅩⅤⅠ.
[5] 中华抗癌协会肝癌专业委员会, 中华医学会肝病学分会肝癌学组, 中国抗癌协会病理专业委员会, 等. 原发性肝癌规范化病理诊断指南(2015年版). 中华肝胆外科杂志, 2015, 21(3):145-151.
[6] 曹曦, 张莹, 南月敏, 等. 血清N-糖组诊断模型在丙型肝炎患者肝纤维化评价中的应用. 中华肝脏病杂志, 2020, 28(12):1023-1029.
[7] Gao S, Chu Q, Liu X, et al. Long noncoding RNA HEIH promotes proliferation, migration and invasion of retinoblastoma cells through miR-194-5p/WEE1 axis. Onco Targets Ther, 2020, 23(13):12033-12041.
[8] Zhao H, Xing G, Wang Y, et al. Long noncoding RNA HEIH promotes melanoma cell proliferation, migration and invasion via inhibiting miR-200b/a/429. Biosci Rep, 2017, 37(3):1-10.
[9] Li P, Zhou B, Lyu Y, et al. LncRNA HEIH regulates cell proliferation and apoptosis through miR-4458/SOCS1 axis in triple-negative breast cancer. Hum Cell, 2019, 32(4):522-528.
[10] Ma Y, Cao D, Li G, et al. Silence of lncRNA HEIH suppressed liver cancer cell growth and metastasis through miR-199a-3p/mTOR axis. J Cell Biochem, 2019, 120(10):17757-17766.
[11] 朱倩, 侍超, 沈晶尧, 等. lncRNA-DUXAP9/DUXAP10水平与肝癌肝切除患者预后的关系. 中华肝胆外科手术学电子杂志, 2020, 9(6):596-601.
[12] Zhang C, Yang X, Qi Q, et al. lncRNA-HEIH in serum and exosomes as a potential biomarker in the HCV-related hepatocellular carcinoma. Cancer Biomark, 2018, 21(3):651-659.
[13] 刘丽芳, 李伟, 陶然, 等. lncRNA4.9干扰慢病毒载体的构建. 中华实验和临床病毒学杂志, 2020, 34(1):83-86.
[14] Si L, Chen J, Yang S, et al. lncRNA HEIH accelerates cell proliferation and inhibits cell senescence by targeting miR-3619-5p/CTTNBP2 axis in ovarian cancer. Menopause, 2020, 27(11):1302-1314.
[15] Chen HY, Su TH, Tseng TC, et al. Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up. J Formos Med Assoc, 2017, 116(9):697-704.
[16] 高淑蔚, 于永波, 刘原虎, 等. 儿童神经母细胞瘤长链非编码RNA LINC00839水平与肿瘤增殖和预后关系. 中国肿瘤防治杂志, 2019, 26(10):695-701.
[17] Zhang S, Ouyang X, Jiang X, et al. Dysregulated serum microRNA expression profile and potential biomarkers in hepatitis C virus-infected patients. Int J Med Sci, 2015, 12(7):590-598.
[18] Tekin F, Gunsar F, Erdogan EI, et al. Seroprevalence of hepatitis A,B, and C viruses in Turkish alcoholic cirrhotics and the impact of hepatitis B on clinical profile. J Infect Dev Ctries, 2015, 9(3):254-258.
[19] Timofte D, Dragos D, Balcangiu-Stroescu AE, et al. Infection with hepatitis C virus in hemodialysis patients: An overview of the diagnosis and prevention rules within a hemodialysis center (Review). Exp Ther Med, 2020, 20(1):109-116.

慢性丙型肝炎患者血清和外泌体LncRNA HEIH水平及其临床意义探讨^*

Clinical implication of LncRNA HEIH in serum and exosomes in patients with chronic hepatitis C

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	姜浩, 张雯, 陈霞. 长效干扰素联合利巴韦林治疗慢性丙型肝炎患者疗效及其对静息能量消耗和营养状态的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 815-818.
[2]	束青华, 张楠楠, 葛勇胜. 不同HCV基因型感染的慢性丙型肝炎和肝硬化患者对重组人干扰素α-2a治疗应答的影响[J]. 实用肝脏病杂志, 2021, 24(6): 899-902.
[3]	韩宏艳, 潘娟, 蒋文平, 张敏. 3D方案治疗基因1b型低病毒载量慢性丙型肝炎患者应答疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(5): 689-692.
[4]	梁玉萍, 粟全球, 张慧, 王佳林. 自身免疫性肝炎患者维生素D缺乏调查及其临床特征分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 464-467.
[5]	安红杰, 徐金凤, 耿华, 葛志胜, 何文艳, 赵崇山, 高美丽, 陈俊, 周东方. FibroScan行肝脏硬度检测和APRI评估慢性丙型肝炎患者肝纤维化程度价值比较^*[J]. 实用肝脏病杂志, 2021, 24(4): 492-495.
[6]	王嘉妮, 刘湧, 周忻, 任传路, 缪惠锴. 慢性丙型肝炎患者血清microRNA-1273g-3p水平预测肝硬化价值分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 496-499.
[7]	罗伟鑫, 刘超群, 许磊波, 刘超, 吴文睿. 不同肺转移潜能的大鼠肝癌细胞外泌体对巨噬细胞转录组的影响[J]. 实用肝脏病杂志, 2021, 24(3): 312-318.
[8]	郝肖伟, 白娜, 郭小军, 陈永刚. 慢性丙型肝炎合并非酒精性脂肪性肝病患者血清A-FABP水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(3): 347-350.
[9]	樊秉栋, 张国华, 王君. 索磷布韦/维帕他韦联合利巴韦林治疗慢性丙型肝炎患者疗效临床研究[J]. 实用肝脏病杂志, 2021, 24(1): 31-34.
[10]	杨晓冬, 贾婷, 张秀灵, 高斯媛, 余向琼, 李冬玲, 喻明丽, 林潮双. 达诺瑞韦联合长效α-干扰素治疗基因3型慢性丙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 35-38.
[11]	刁青, 段银环, 苗亮, 王守云. DAAs治疗丙型肝炎肝硬化患者疗效及安全性研究^*[J]. 实用肝脏病杂志, 2020, 23(6): 841-844.
[12]	周长雄, 于文虎, 金笛. 艾尔巴韦/格拉瑞韦治疗慢性丙型肝炎患者疗效初步观察[J]. 实用肝脏病杂志, 2020, 23(5): 646-649.
[13]	徐金凤, 安红杰, 何文艳, 艾红, 赵崇山, 赵应飞, 董波, 周丽华, 吴晶. PR方案治疗慢性丙型肝炎患者ITPA基因rs1127354位点多态性与利巴韦林相关性溶血关系探讨^*[J]. 实用肝脏病杂志, 2020, 23(4): 500-503.
[14]	符垂师,张杰伟. α干扰素联合利巴韦林治疗儿童丙型肝炎患者病毒学应答率分析[J]. 实用肝脏病杂志, 2020, 23(3): 344-347.
[15]	张晓伟, 钟蕊. 索磷布韦和维帕他韦联合利巴韦林治疗基因2、3型慢性丙型肝炎患者近期疗效和耐受性观察^*[J]. 实用肝脏病杂志, 2020, 23(2): 191-194.